Budesonide capsules for IgA kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old
- Kidney biopsy in the past 2 weeks showing IgA nephropathy (primary type only)
- Kidney function not too low (eGFR ≥ 20)
- Protein in urine between 0.5–3.5 grams per day
- No recent or ongoing infections like hepatitis, TB, or HIV
- Willing to take budesonide capsules plus standard supportive care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
This trial tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help protect kidney function. Participants must have a recent kidney biopsy showing certain features and stable kidney function.
This study tests a long-term treatment for people with IgA nephropathy, a kidney disease. It aims to see if continuing the treatment is safe and helpful over a longer period.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Hear when a new IgA Glomerulonephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.